Effect of magnesium on stress-induced hyperglycemia

Evaluation effects of magnesium loading dose on insulin resistance and stress-induced hyperglycemia in critically ill patients admitted to ICU

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201611013449N22

Enrollment

Registered

2016-11-17

Start date

2016-09-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stress induced hyperglycemia. Postprocedural hypoinsulinaemia

Interventions

Intervention 1: Intervention group: 25 patients will be randomly assigned to receive magnesium sulfate (7.5 g in 500 ml of normal saline over 8 hours) intravenously. Intervention 2: Control group: 25

Treatment - Drugs

Placebo

Intervention group: 25 patients will be randomly assigned to receive magnesium sulfate (7.5 g in 500 ml of normal saline over 8 hours) intravenously.

Control group: 25 patients will be randomly assigned to receive 500 mL normal saline over 8 hours intravenously.

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Non-diabetic adult patients (18–65 years old) with stress induced hyperglycemia (at least two fasting blood glucose more than 126 mg/dl) within the first 24 hour of admission to the ICU will be included. Exclusion criteria: Known cases of diabetes mellitus, patients with hypermagnesemia [Mg]> 3.5 mg / dL, hypomagnesemia [Mg] 6.5%, drug toxicity and pregnant patients will be excluded from the study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Insulin resistance according to HOMA-score. Timepoint: At day 0 - day 3. Method of measurement: It will be calculated by FBS (is measured with a blood auto-analyzer in mg/dl) and serum insulin (is measured with insulin kit and ELISA method in µmol/L ).;Blood glucose level. Timepoint: At day 0-day 1- day 2- day 3, as every 6 hours per day. Method of measurement: By a blood auto-analyzer in mg/dl.;Adiponectin plasma concentrations (as a insulin resistance biochemical marker). Timepoint: At day 0 - day 3. Method of measurement: By adiponectin kit and ELISA method in µg/ml.;Serum magnesium level. Timepoint: At day 0- day 1- day 2- day 3. Method of measurement: By spectrophotometry and Pars-Azmoon kit in mg/dl.;Intracellular magnesium concentration (RBC magnesium level). Timepoint: At day 0- day 1- day 2- day 3. Method of measurement: By spectrophotometry and Pars-Azmoon kit in mg/dl.	—

Measure

Time frame

Insulin resistance according to HOMA-score. Timepoint: At day 0 - day 3. Method of measurement: It will be calculated by FBS (is measured with a blood auto-analyzer in mg/dl) and serum insulin (is measured with insulin kit and ELISA method in µmol/L ).;Blood glucose level. Timepoint: At day 0-day 1- day 2- day 3, as every 6 hours per day. Method of measurement: By a blood auto-analyzer in mg/dl.;Adiponectin plasma concentrations (as a insulin resistance biochemical marker). Timepoint: At day 0 - day 3. Method of measurement: By adiponectin kit and ELISA method in µg/ml.;Serum magnesium level. Timepoint: At day 0- day 1- day 2- day 3. Method of measurement: By spectrophotometry and Pars-Azmoon kit in mg/dl.;Intracellular magnesium concentration (RBC magnesium level). Timepoint: At day 0- day 1- day 2- day 3. Method of measurement: By spectrophotometry and Pars-Azmoon kit in mg/dl.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHossein Khalili

Tehran University of Medical Sciences

khalilih@tums.ac.ir+98 21 6658 1598

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026